找回密碼
 To register

QQ登錄

只需一步，快速開始

掃一掃，訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Dose Finding and Beyond in Biopharmaceutical Development; Jingjing Ye,Ding-Geng Chen,Joseph C. Cappelleri Book 2025 The Editor(s) (if appl

[復(fù)制鏈接]
查看: 26676|回復(fù): 46
樓主
發(fā)表于 2025-3-21 18:44:52 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱Dose Finding and Beyond in Biopharmaceutical Development
編輯Jingjing Ye,Ding-Geng Chen,Joseph C. Cappelleri
視頻videohttp://file.papertrans.cn/285/284821/284821.mp4
概述Provides a natural discourse on the major advances over the last 20 years.Emphasizes case studies and best practices in dose-finding/dose-optimization in the evolving drug development paradigm.Supplie
叢書名稱ICSA Book Series in Statistics
圖書封面Titlebook: Dose Finding and Beyond in Biopharmaceutical Development; Jingjing Ye,Ding-Geng Chen,Joseph C. Cappelleri Book 2025 The Editor(s) (if appl
描述.This book covers topics in 2 parts: 1) Review of FDA Guidance, 2) Novel Designs and Analyses. While covering basic principles of dose finding, this book details advancements made in drug development...Finding the right dose(s) is one of the most important objectives in new drug development. In Phase I clinical development, one of the objectives is to escalate test doses from low to high. The low doses should be safe, then escalate up to the maximally tolerable dose (MTD). Phase Ⅱ clinical trials then lower test doses to the minimal efficacious dose (MinED). Dose range of a study drug can be thought of as the doses between MinED and MTD. From this dose range, one or a few doses are selected for Phase Ⅲ confirmation. In practice, dose finding is a very difficult in every phase of clinical development for new drugs...The editors brought distinguished researchers and practitioners in biopharmaceuticals and universities, to discuss the statistical procedures, useful methods, and their novel applications in dose finding. The chapters in the book present emerging topics in dose-finding and related interdisciplinary areas. This timely book is a valuable resource to stimulate the developme
出版日期Book 2025
關(guān)鍵詞Dose-finding designs; dose response clinical trials; clinical research; drug development; Project Optimu
版次1
doihttps://doi.org/10.1007/978-3-031-67110-4
isbn_softcover978-3-031-67112-8
isbn_ebook978-3-031-67110-4Series ISSN 2199-0980 Series E-ISSN 2199-0999
issn_series 2199-0980
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

書目名稱Dose Finding and Beyond in Biopharmaceutical Development影響因子(影響力)




書目名稱Dose Finding and Beyond in Biopharmaceutical Development影響因子(影響力)學(xué)科排名




書目名稱Dose Finding and Beyond in Biopharmaceutical Development網(wǎng)絡(luò)公開度




書目名稱Dose Finding and Beyond in Biopharmaceutical Development網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Dose Finding and Beyond in Biopharmaceutical Development被引頻次




書目名稱Dose Finding and Beyond in Biopharmaceutical Development被引頻次學(xué)科排名




書目名稱Dose Finding and Beyond in Biopharmaceutical Development年度引用




書目名稱Dose Finding and Beyond in Biopharmaceutical Development年度引用學(xué)科排名




書目名稱Dose Finding and Beyond in Biopharmaceutical Development讀者反饋




書目名稱Dose Finding and Beyond in Biopharmaceutical Development讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics
 

0票 0%

Better Implies Difficulty
 

0票 0%

Good and Satisfactory
 

0票 0%

Adverse Performance
 

0票 0%

Disdainful Garbage
您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:38:18 | 只看該作者
板凳
發(fā)表于 2025-3-22 04:20:17 | 只看該作者
地板
發(fā)表于 2025-3-22 07:35:41 | 只看該作者
5#
發(fā)表于 2025-3-22 08:54:56 | 只看該作者
6#
發(fā)表于 2025-3-22 16:27:36 | 只看該作者
https://doi.org/10.1007/978-3-642-92507-8luding leukemia 2023, kidney cancer, and melanoma (Siegel, CA Cancer J Clin 73(1):17–48, 2023). The development of targeted therapies, in particular, has dramatically altered the therapeutic landscape and improved outcomes for patients. Despite the seismic changes that have occurred in the field, so
7#
發(fā)表于 2025-3-22 18:05:17 | 只看該作者
dbreaking initiative had fundamentally changed the oncology dose-finding paradigm: discouraging outdated conventions since the era of cytotoxic agents (identifying the maximum tolerated dose, MTD), and embracing new practices of identifying the optimal dosage among multiple doses based on totality o
8#
發(fā)表于 2025-3-22 22:08:46 | 只看該作者
Bits, Bytes, Words and Numbers,e treatments, oncology trials need to start human research at a lower dose level and then move up and down through some dose levels in a process called dose finding that helps determine a safe dose level. The toxicity of these oncology drugs is always assumed to increase with dose. However, unlike i
9#
發(fā)表于 2025-3-23 03:41:01 | 只看該作者
10#
發(fā)表于 2025-3-23 06:27:12 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-26 00:13
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
乐至县| 怀安县| 荣成市| 阿拉善盟| 乌兰县| 芦山县| 镇江市| 沽源县| 鄄城县| 榕江县| 迁安市| 定远县| 五指山市| 宁蒗| 黑河市| 桦甸市| 绥化市| 高碑店市| 鄂尔多斯市| 太湖县| 宜宾县| 大竹县| 上栗县| 静安区| 庄河市| 扎兰屯市| 介休市| 财经| 安龙县| 蓬安县| 青州市| 台中市| 九龙县| 龙口市| 蓝田县| 汶上县| 乌苏市| 莲花县| 仙桃市| 兰州市| 响水县|